{
    "nct_id": "NCT03455829",
    "official_title": "Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination With Osimertinib in Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)",
    "inclusion_criteria": "* Confirmed EGFR mutation for non-small cell lung cancer associated with EGFR TKI sensitivity\n* For Part 2, EGFR T790M mutation-positive tumor status\n* Left ventricular ejection fraction (LVEF) â‰¥ institution's lower limit of the reference range\n* For Part 1, evaluable or measurable disease as defined by RECIST, Version 1.1\n* For Part 2, measurable disease as defined by RECIST, Version 1.1\n* ECOG performance status 0 to 1\n* Adequate organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with EGFR TKI within 9 days of first study dose\n* For Part 1, prior treatment with more than 2 prior lines of chemotherapy for advanced NSCLC\n* For Part 2, prior treatment with osimertinib or other T790M active EGFR TKI\n* For Part 2, prior chemotherapy for advanced NSCLC\n* Active uncontrolled/symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease\n* Investigational drug within 3 months or 5 half-lives, whichever is longer, of first study dose\n* Concurrent radiotherapy, radiotherapy within 28 days of first study dose, previous radiotherapy to the target lesion sites, or prior radiotherapy to > 25% of bone marrow\n* Prior hematopoietic stem cell or bone marrow transplantation",
    "miscellaneous_criteria": ""
}